School of Medicine
Showing 501-520 of 838 Results
-
Yair Blumenfeld, MD
Professor of Obstetrics and Gynecology (Maternal Fetal Medicine)
Current Research and Scholarly Interestsprenatal diagnosis, genetics, clinical obstetrics
-
Mark S. Blumenkranz, MD, MMS
H. J. Smead Professor of Ophthalmology, Emeritus
Current Research and Scholarly InterestsClinical Interest and Research
My primary areas of interest are in the diagnosis, medical and surgical treatment of vitreal retinal diseases. These principally include age-related macular degeneration and other diseases of the macula, and tractional syndromes, diabetic retinopathy, and complex forms of retinal detachment. I have been interested in the development of novel technology to diagnose and treat these diseases, including new forms of imaging, laser delivery systems, other microsurgical tools, and new drugs and drug delivery systems that inhibit new blood vessel growth, scarring and intraocular inflammation. I have been actively involved in translational research in the laboratory as well as technology transfer associated with that research for a variety of new therapies that have received FDA clearance and been introduced into clinical practice over the past 30 years.
Administrative and Community Service
I have served on the Board of Directors of a variety of voluntary education and service organizations, including the Corporation of Brown University, multiple scientific advisory boards and various philanthropic and research organizations. -
Paul D. Blumenthal, MD, MPH
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsImproving Access to Family Planning Services in Low Resource Settings:
Through a collaboration with Population Services International, the Stanford Program for International Reproductive Education and Services (SPIRES) provides technical direction in a program designed to improve access to and uptake of family planning, particularly Long Acting Reversible Contraception (LARC) such as IUDs and implants, in 14 developing countries globally. The first year saw insertion of over 280,000 IUDs. -
Fernando E Boada
Professor of Radiology (Radiological Sciences Laboratory)
BioFernando Boada is a Professor of Radiology and Associate Chair for Basic Science Translational Research at Stanford University Medical School. [1] He joined Stanford in 2021 after being Professor of Radiology, Psychiatry and Neurosurgery at New York University Medical School and the Director of the Center for Advanced Imaging Innovation and Research. [1] Prior to joining NYU in 2012, Dr. Boada directed the MR Research Center (MRRC) at the University of Pittsburgh for ten years. [1] His research efforts have been focused on the development of novel MRI techniques for addressing open neuroimaging questions in a translational setting.
-
Christina Bodurow
Affiliate, Medicine - Med/Gastroenterology and Hepatology
BioChris has a proven record of accomplishment delivering results to pharmaceutical and scientific organizations, including 33 years of management experience at Eli Lilly and Company, within Lilly Research Laboratories (LRL), 3.5 years in a global leadership role at IQVIA, and now as Deputy Director and COO of a significant NIH/NIAID research grant at Stanford University Medical School.
Over the years, Chris has served as a leader of multiple global teams in drug development and R&D Operations, representing her organizations in multiple external settings, including scientific, academic, drug development and R&D Operations forums.
In, December 2017, Chris retired from Lilly as Sr. Director, External Sourcing, leading an enterprise-wide R&D operations group that partnered with LRL functions to assess, on-board, and govern third party organizations across the entire drug development value chain, from pre-clinical, through clinical, regulatory, safety, health outcomes, product and device development, and diagnostics. The division consolidated both corporate and external requirements to deliver high-quality, risk-based, third party governance, oversight and alliance management for the LRL Development organization.
In February 2019, Chris joined IQVIA as the Vice-President of Strategy & Operations for DSSR, and subsequently moved in the role of Vice-President, Global Regulatory Affairs.
Specialties: Pharmaceutical Development, R&D Operations, Molecule Submission/Approval/Launch, Product Lifecycle Planning and Development, R&D Business Systems design and delivery. Third Party Management, Women's Leadership Development.
